||Kenichi HORISAWA, Atsushi SUZUKI, Direct cell-fate conversion of somatic cells: Toward regenerative medicine and industries, Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences, 10.2183/pjab.96.012, 2020.04.
||Shizuka Miura, Atsushi Suzuki, Brief summary of the current protocols for generating intestinal organoids, Development Growth and Differentiation, 10.1111/dgd.12559, 2018.08, The intestine has fundamental functions for the maintenance of homeostasis, including food digestion and nutrient/water absorption. Although the lumen of the intestine is always exposed to pathogens, intestinal epithelial cells form monolayer sheets that act as an epithelial barrier to prevent the invasion of pathogens. Thus, disruption of the intestinal epithelial barrier causes inflammatory bowel diseases. To investigate the details of these intractable intestinal diseases, it is necessary to analyze the characteristics of intestinal epithelial cells in vitro. However, it is difficult to maintain and propagate intestinal epithelial cells in culture. Recently, intestinal organoid culture systems have been established, in which differentiated intestinal epithelial lineage cells can be continuously produced from intestinal stem cells and form epithelial organoids with crypt-like structures in long-term culture. Moreover, intestinal epithelial organoids can be generated not only from intestinal tissue-derived cells, embryonic stem cells, and induced pluripotent stem cells, but also by inducing direct conversion of nonintestinal somatic cells into intestinal epithelial cells. These intestinal organoids can be used in basic studies for understanding the mechanisms underlying intestinal development and diseases and will be applied in future transplantation therapy and drug discovery to treat intestinal diseases..
||Masaki KAWAMATA, Atsushi SUZUKI, Cell fate modification toward the hepatic lineage by extrinsic factors, The Journal of Biochemistry, 2017.04.
||Takeshi GOYA, Atsushi SUZUKI, Novel methods for the treatment of liver fibrosis using in vivo direct reprogramming technology, Stem Cell Investigation, 2016.12.
||Kenichi HORISAWA, Atsushi SUZUKI, Cell-based regenerative therapy for liver disease, Innovative Medicine: Basic Research and Development, Springer Japan (Tokyo), 2015.12.
||Atsushi SUZUKI, Evidence of cell-fate conversion from hepatocytes to cholangiocytes in the injured liver: in vivo genetic lineage-tracing approaches, Current Opinion in Gastroenterology, 2015.05.
||Atsushi SUZUKI, Liver regeneration: a unique and flexible reaction depending on the type of injury, Genes to Cells, 2015.02.
||Atsushi SUZUKI, Direct reprogramming, Inflammation and Regeneration, 2014.12.
||Atsushi SUZUKI, Artificial induction and disease-related conversion of the hepatic fate, Current Opinion in Genetics & Development, 2013.05.
||Yasuo TAKASHIMA, Atsushi SUZUKI, Regulation of organogenesis and stem cell properties by T-box transcription factors, Cellular and Molecular Life Sciences, 2013.03.